Articles dans des revues avec comité de lecture (82)
  1. 1. Berghuis, D., Mehyar, L. L., Abu-Arja, R., Albert, M. H., Barnum, J. J., von Bernuth, H., Elfeky, R., Lewalle, P., Laberko, A., Ghosh, S., Slatter, M. A., Weemaes, C. M., Yesilipek, A., Sirait, T., Neven, B., Gennery, A. R., & Lankester, A. C. (2024). Allogeneic Hematopoietic Stem Cell Transplantation in Immunodeficiency—Centromeric Instability—Facial Dysmorphism (ICF) Syndrome: an EBMT/ESID Inborn Errors Working Party Study. Journal of clinical immunology, 44(8), 182. doi:10.1007/s10875-024-01786-7
  2. 2. Michiels, S., Tricas-Sauras, S., Salaroli, A., Bron, D., Lewalle, P., Vanschoenbeek, K., Poirel, H. A., & Kirakoya, F. (2024). Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data. Patient Preference and Adherence, Volume 18, 1991-2006. doi:10.2147/PPA.S472478
  3. 3. Otmani, K., Rouas, R., Berehab, M., & Lewalle, P. (2024). The regulatory mechanisms of oncomiRs in cancer. Biomedicine & pharmacotherapy, 171, 116165. doi:10.1016/j.biopha.2024.116165
  4. 4. Najar, M., Bouhtit, F., Rahmani, S., Bouali, A., Melki, R., Najimi, M., Lewalle, P., & Merimi, M. (2024). The immunogenic profile and immunomodulatory function of mesenchymal stromal / stem cells in the presence of Ptychotis verticillata. Heliyon, 10(3), e24822. doi:10.1016/j.heliyon.2024.e24822
  5. 5. Otmani, K., Rouas, R., Lagneaux, L., Krayem, M., Duvillier, H., Berehab, M., & Lewalle, P. (2023). Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF-κB signaling pathways. Cell Communication and Signaling, 21(1), 253. doi:10.1186/s12964-023-01259-1
  6. 6. Otmani, K., Rouas, R., & Lewalle, P. (2022). OncomiRs as noncoding RNAs having functions in cancer: Their role in immune suppression and clinical implications. Frontiers in immunology, 13, 913951. doi:10.3389/fimmu.2022.913951
  7. 7. Bouhtit, F., Najar, M., Rahmani, S., Melki, R., Najimi, M., Sadki, K., Boukhatem, N., Twizere, J.-C., Meuleman, N., Lewalle, P., Lagneaux, L., & Merimi, M. (2022). Bioscreening and pre-clinical evaluation of the impact of bioactive molecules from Ptychotis verticillata on the multilineage potential of mesenchymal stromal cells towards immune- and inflammation-mediated diseases. Inflammation research, 71(7-8), 887-898. doi:10.1007/s00011-022-01573-3
  8. 8. Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., & Salaroli, A. (2022). New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy. International journal of molecular sciences, 23(7), 3887. doi:10.3390/ijms23073887
  9. 9. Najar, M., Melki, R., Khalife, F., Lagneaux, L., Bouhtit, F., Moussa Agha, D., Fahmi, H., Lewalle, P., Fayyad Kazan, M., & Merimi, M. (2022). Therapeutic Mesenchymal Stem/Stromal Cells: Value, Challenges and Optimization. Frontiers in Cell and Developmental Biology, 9, 716853. doi:10.3389/fcell.2021.716853
  10. 10. Otmani, K., & Lewalle, P. (2021). Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications. Frontiers in oncology, 11, 708765. doi:10.3389/fonc.2021.708765
  11. 11. Merimi, M., El-Majzoub, R., Lagneaux, L., Moussa Agha, D., Bouhtit, F., Meuleman, N., Fahmi, H., Lewalle, P., Fayyad Kazan, M., & Najar, M. (2021). The Therapeutic Potential of Mesenchymal Stromal Cells for Regenerative Medicine: Current Knowledge and Future Understandings. Frontiers in Cell and Developmental Biology, 9. doi:10.3389/fcell.2021.661532
  12. 12. Merimi, M., Buyl, K., Daassi, D., Rodrigues, R. M., Melki, R., Lewalle, P., Vanhaecke, T., Fahmi, H., Rogiers, V., Lagneaux, L., De Kock, J., & Najar, M. (2021). Transcriptional profile of cytokines, regulatory mediators and tlr in mesenchymal stromal cells after inflammatory signaling and cell-passaging. International journal of molecular sciences, 22(14), 7309. doi:10.3390/ijms22147309
    13. << Précédent 1 2 3 4 5 6 7 8 Suivant >>